Literature DB >> 17629471

Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?

Raid A M Al-Showair1, Walid Y Tarsin, Khaled H Assi, Stanley B Pearson, Henry Chrystyn.   

Abstract

The inhalation rate is important when patients use an inhaler. Dry powder inhalers (DPIs) require an inhalation rate >30 L min(-1) whereas metered dose inhalers (MDIs) should be used at <90 L min(-1). Within the setting of a routine clinic, we have measured peak inhalation flows (PIF) of COPD patients when they used a Diskus (SDSK), Turbuhaler (STBH), Handihaler (SHAND) and MDI. Subjects were then randomised into trained (VT) and non-trained (NT) groups. One hundred and sixty-three patients with a mean (S.D.) age and % predicted FEV(1) of 72.5 (9.9) years and 47.8 (22.2)% completed the study. Of the patients, 4.9%, 14.2% and 57.0% inhaled <30 L min(-1) through SDSK, STHB and SHAND, respectively and 59.5% inhaled >90 L min(-1) with the MDI. Generally, the more severe the COPD, the slower was their PIF with all inhalers. The MDI PIF values in the VT group (n=84) post-training were significantly (p<0.001) slower but there was no change for the DPIs. Of the 55 VT patients inhaling >90 L min(-1) through the MDI only 7 (p<0.001) inhaled too fast post-training. Pre-training 3, 15 and 46 VT subjects inhaled <30 L min(-1) through the SDSK, STBH and SHAND and after training none, 5 and 26 did not inhale faster than this minimum required rate. Some COPD patients have problems achieving required PIFs through DPIs but training is useful to help some exceed the minimum required rate despite only small improvements. The patients found it easier to slow their PIF through the MDI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17629471     DOI: 10.1016/j.rmed.2007.06.008

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  62 in total

1.  Postapproval Development Options in COPD: A Case Study in Value-Based Healthcare Systems.

Authors:  Michael F Murphy; Paola Antonini; Zhihong Vicki Lai
Journal:  Am Health Drug Benefits       Date:  2011-01

2.  Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation.

Authors:  Gulshan Sharma; Donald A Mahler; Valerie M Mayorga; Kathleen L Deering; Oing Harshaw; Vaidyanathan Ganapathy
Journal:  Chronic Obstr Pulm Dis       Date:  2017-07-15

3.  Personalization of Device Therapy - Prime Time for Peak Inspiratory Flow Rate.

Authors:  Chee H Loh; Jill A Ohar
Journal:  Chronic Obstr Pulm Dis       Date:  2017-07-14

Review 4.  Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.

Authors:  Sohini Ghosh; Jill A Ohar; M Bradley Drummond
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-09-21       Impact factor: 2.849

Review 5.  Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.

Authors:  Agnieszka Sliwka; Milosz Jankowski; Iwona Gross-Sondej; Monika Storman; Roman Nowobilski; Malgorzata M Bala
Journal:  Cochrane Database Syst Rev       Date:  2018-08-24

6.  Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters.

Authors:  L Pekka Malmberg; Paula Rytilä; Pertti Happonen; Tari Haahtela
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-08-09

7.  Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®).

Authors:  L Pekka Malmberg; Mark L Everard; Jussi Haikarainen; Satu Lähelmä
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-06-30       Impact factor: 2.849

8.  [Chronic obstructive pulmonary disease : new pharmacotherapeutic options].

Authors:  T Greulich; A R Koczulla; C Vogelmeier
Journal:  Internist (Berl)       Date:  2012-11       Impact factor: 0.743

9.  Medication Use Before and After Hospitalization for Chronic Obstructive Pulmonary Disease in a Cohort of Elderly Patients with a Medicare Advantage Plan.

Authors:  Qingqing Xu; Sarah S Laxa; Omar Serna; Sujit S Sansgiry
Journal:  Am Health Drug Benefits       Date:  2020-02

10.  Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate.

Authors:  Donald A Mahler; Jill A Ohar; Chris N Barnes; Edmund J Moran; Srikanth Pendyala; Glenn D Crater
Journal:  Chronic Obstr Pulm Dis       Date:  2019-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.